A randomized, phase III clinical trial conducted has demonstrated that the addition of crenolanib to salvage chemotherapy significantly improves outcomes in adults with AML harboring FLT3 mutations.

---

An abstract is unavailable.

In this quality improvement study, emergency physicians successfully adopted oral medications for treating agitation, primarily from intoxication.

---

Question Can emergency physicians adopt using oral medications as first-line treatment for agitation primarily from intoxication?

Findings In this quality improvement study evaluating 460 600 ED encounters, the proportion of patients receiving their first sedating medication orally increased from 7% to 31% after 1 year of the intervention, while time to adequate sedation and adverse events, measured prospectively during implementation, were not different between oral and intramuscular routes.

Background and ObjectivesIn cervical spondylotic myelopathy (CSM), compression may not be evident in the neutral position, potentially leading to misdiagnosis and delayed treatment. We sought to assess the utility of flexion-extension MRI in revealing…

Lots of interesting information! The Zevaskyn (“a first cell-sheet-based gene therapy”) approval for treating epidermolysis bullosa (EB) is particularly uplifting. Back in high school, I knew someone with EB. It is a devastating disease. On the less happy side, an AAV9 therapy and an oncolytic virus therapy were rejected this year. [ https://www.nature.com/articles/d41573-026-00001-z](https://www.nature.com/articles/d41573-026-00001-z)

---

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of University of Miami Miller School of Medicine.

None of the 18 patients who completed up to six cycles of treatment with the antibody linvoseltamab had detectable disease on highly sensitive tests. This preliminary success suggests linvoseltamab, a bispecific antibody, could allow patients to avoid bone marrow transplants, which involve intense, high-potency chemotherapy. It also points to the long-term possibility of improving patients’ odds against this disease.

Lead researcher Dickran Kazandjian, M.D., a Sylvester physician and professor in the Myeloma Division at the Miller School, presented updated results today at the American Society of Hematology meeting in Orlando. Dr. Kazandjian conducted the research in collaboration with C. Ola Landgren, M.D., Ph.D., director of Sylvester Myeloma Institute.

“These patients received modern and effective, up-front treatment that eliminated 90% of their tumor,” said Dr. Kazandjian. “Usually, patients like these would receive high-dose chemotherapy and transplant. Instead, we give them a treatment with the drug linvoseltamab.”

---

Sylvester Comprehensive Cancer Center researchers are investigating ways to eradicate residual traces of multiple myeloma.